Results 121 to 130 of about 11,407 (242)
BiosensorsThe use of adalimumab biosimilars has become increasingly common in clinical practice, reflecting their growing acceptance and efficacy as therapeutic alternatives to reference biologics.
Andrea Di Santo +8 more
doaj +1 more source
Moving beyond a legacy paradigm: A vision for equitable access to quality medicines in Africa
International Journal of Gynecology &Obstetrics, Volume 172, Issue S2, Page S44-S50, June 2026.Abstract Ensuring the availability of quality medicines is fundamental to achieving health outcomes and safeguarding public health. However, in many low‐ and middle‐income countries, especially across Africa, the current quality assurance paradigm—largely driven by historical donor preferences for WHO prequalification and stringent regulatory authority
Naoko Doi +9 more
wiley +1 more source
Introducing New Biosimilars Into Current Treatment Algorithms
, 2016 Three biosimilar products are now licensed for the treatment of rheumatic diseases in Europe. The European Medicines Agency (EMA) requires that similarity between a biosimilar and its reference product is demonstrated using a rigorous, stepwise process ...
Tore K. Kvien +3 more
core
New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa
JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender +2 more
wiley +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.ABSTRACT Background and Aims In 2019, British Columbia (BC) became the first jurisdiction in North America to introduce a mandatory non‐medical switching (NMS) policy requiring patients with Crohn's disease (CD) and ulcerative colitis (UC) to be switched from originator biologics to biosimilar equivalents.
Mark Harrison +8 more
wiley +1 more source
International Journal of Rheumatic Diseases, Volume 29, Issue 6, June 2026.ABSTRACT Purpose To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods This prospective
Preeti Dhanasekaran +9 more
wiley +1 more source
A QUM partnership approach to regulating biosimilars in Australia
, 2014 Despite the realisation of the potential implications from biosimilars is relatively recent, much has already been written about raising the awareness of differences between biosimilars and originating/ reference listed (innovator) pharmaceuticals.
Lim, David +4 more
core
Understanding and Incentivizing Biosimilars
, 2012 Congress recently passed the Biosimilars Act in an attempt to replicate the success that generic small molecule drugs have enjoyed under the Hatch-Waxman Act.
Feldman, Robin, Kanter, Jason
core +1 more source
A Case for Anti‐IgE Vaccination
Allergy, Volume 81, Issue 6, Page 2001-2013, June 2026.ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff +3 more
wiley +1 more source